期刊
LANCET
卷 381, 期 9869, 页码 845-860出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)61897-2
关键词
-
资金
- European Union
- UK Medical Research Council
- Wellcome Trust
- Association Francaise Contre les Myopathies
- Muscular Dystrophy Campaign
- Great Ormond Street Hospital Biomedical Research Centre
- Muscular Dystrophy Association USA
- GlaxoSmithKline
- Trophos
- British Heart Foundation
- AVI BioPharma
- PTC Therapeutics
- Parent Project NL
- SMA Europe
- Italian Telethon
- MRC [MR/K000608/1] Funding Source: UKRI
- Medical Research Council [MR/K000608/1] Funding Source: researchfish
Muscular dystrophies are a heterogeneous group of inherited disorders that share similar clinical features and dystrophic changes on muscle biopsy. An improved understanding of their molecular bases has led to more accurate definitions of the clinical features associated with known subtypes. Knowledge of disease-specific complications, implementation of anticipatory care, and medical advances have changed the standard of care, with an overall improvement in the clinical course, survival, and quality of life of affected people. A better understanding of the mechanisms underlying the molecular pathogenesis of several disorders and the availability of preclinical models are leading to several new experimental approaches, some of which are already in clinical trials. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, and therapeutic developments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据